Search results for "adipokine"

showing 10 items of 124 documents

Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome.

2009

Central fat distribution is increased in anovulatory women with polycystic ovary syndrome (PCOS) compared with ovulatory PCOS and matched controls. Among secreted adipocytokines, this is reflected mainly in lower levels of adiponectin.

AdultLeptinOvulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectAdipokineAdipose tissueBiologyAnovulationInsulin resistanceAdipokinesInternal medicinemedicineBody Fat DistributionHumansNicotinamide PhosphoribosyltransferaseOvulationmedia_commonAdiponectinLeptinnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryfat distribution; polycystic ovary syndromeLipidsfemale genital diseases and pregnancy complicationsEndocrinologyC-Reactive ProteinPhenotypeReproductive Medicinefat distributionCase-Control StudiesFemaleAdiponectinInsulin ResistanceWaist CircumferenceRetinol-Binding Proteins PlasmaAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Inflammatory markers and cardiovascular risk in the metabolic syndrome

2011

Elevated blood glucose, obesity, high blood pressure, elevated triglycerides and low high density lipoprotein (HDL) cholesterol are well accepted risk factors in the development of coronary artery disease. Clustering of at least three of these factors in an individual is defined as metabolic syndrome (MetS). Obesity is a central pathological mechanism in the disease and it is expected that the incidence of this condition will increase dramatically within the next years. The visceral adipose tissue is not only an energy depot but also an endocrine organ which produces a large number of bioactive molecules, the so called adipokines. In the setting of obesity, the over-production of proinflamm…

AdultLeptinRiskAdolescentAngiotensinogenAdipokineAdipose tissueDiseaseIntra-Abdominal FatBioinformaticsCoronary artery diseasePathogenesisInsulin resistancePlasminogen Activator Inhibitor 1medicineHumansResistinObesityLife StyleChemokine CCL2InflammationMetabolic SyndromeInterleukin-6Tumor Necrosis Factor-alphabusiness.industryAtherosclerosisPrognosismedicine.diseaseObesityPlaque AtheroscleroticCardiovascular DiseasesAdiponectinEndothelium VascularInsulin ResistanceMetabolic syndromebusinessBiomarkersFrontiers in Bioscience
researchProduct

The role of adiponectin and leptin in the treatment of ovarian cancer patients

2019

Introduction: Ovarian cancer is most frequently detected in the advanced stage. Although its pathogenesis is not fully elucidated, it is assumed that body susceptibility and hormonal disorders are responsible. The role of some cytokines as predictors in the treatment process is still investigated. The aim of the study was to determine the relationship of adiponectin and leptin with the disease severity and response to chemotherapy. Material and methods: Forty-three ovarian cancer patients were treated by systemic treatment. Patients received 5–7 cycles of chemotherapy — paclitaxel/carboplatin with or without bevacizumab. Using standard ELISA kits before and after chemotherapy, adiponectin a…

AdultLeptinmedicine.medical_specialtyPaclitaxelBevacizumabEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokine030209 endocrinology & metabolismGastroenterologyCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyBlood serumInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedAged 80 and overOvarian NeoplasmsChemotherapyAdiponectinbusiness.industryLeptinMiddle Agedmedicine.diseaseCarboplatinBevacizumabTreatment OutcomechemistryFemaleAdiponectinOvarian cancerbusinessBiomarkershormones hormone substitutes and hormone antagonistsmedicine.drugEndokrynologia Polska
researchProduct

Evidence for altered adipocyte function in polycystic ovary syndrome.

2005

Background: Adipocytokines are produced by adipose tissue and have been thought to be related to insulin resistance and other health consequences. We measured leptin, adiponectin, and resistin simultaneously in women with polycystic ovary syndrome (PCOS) and age- and weight-matched controls. Our hypothesis was that these simultaneous measurements would help determine whether adipocytokine secretion is abnormal in PCOS independent of body mass and whether these levels are related to insulin resistance as well as other hormonal changes. Methods: Fifty-two women with PCOS and 45 normal ovulatory women who were age- and weight-matched were studied. Blood was obtained for adipocytokines (leptin,…

AdultLeptinmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismAdipose tissueAdipokineBiologyBody Mass Indexchemistry.chemical_compoundresistin polycystic ovary syndromeEndocrinologyInsulin resistanceRETN protein humanInternal medicineAdipocytemedicineIntercellular Signaling Peptides and ProteinAdipocytesHumansResistinAdiponectinLeptinnutritional and metabolic diseasesGeneral Medicinemedicine.diseasePolycystic ovaryleptin; adiponectin; resistin polycystic ovary syndromeEndocrinologychemistryCase-Control StudiesHormones EctopicIntercellular Signaling Peptides and ProteinsResistinFemaleAdiponectinInsulin Resistancehormones hormone substitutes and hormone antagonistsPolycystic Ovary SyndromeEuropean journal of endocrinology
researchProduct

Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.

2012

Context: The visceral adiposity index (VAI) has proved to be a marker of visceral adipose dysfunction, strongly associated with insulin sensitivity in both the general and specific populations of patients at metabolic risk. Objective: The objective of the study was to test VAI as a useful tool to assess early metabolic risk in acromegaly. Patients: Twenty-four newly diagnosed acromegalic patients (11 women and 13 men, aged 54.9 ± 13.6 yr) were grouped into those with normal (group A, n = 13, 54.2%) and those with high VAI (group B, n = 11, 45.8%). Outcome Measures: Glucose, hemoglobin A1c, nadir and area under the curve (AUC) of GH (AUCGH) during the oral glucose tolerance test, AUCCpeptide…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryAdipokineContext (language use)Intra-Abdominal FatBiochemistrySettore MED/13 - EndocrinologiaEndocrinologyInsulin resistanceAdipokinesInternal medicineAcromegalymedicineAcromegaly Visceral Adiposity IndexHumansInsulin-Like Growth Factor IAdiposityAgedAdiponectinbusiness.industryHuman Growth HormoneLeptinBiochemistry (medical)Area under the curveMiddle Agedmedicine.diseaseEndocrinologyArea Under CurveAcromegalyFemaleMetabolic syndromeInsulin ResistancebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction.

2007

. Objective.  Resistin is an adipokine that has been suggested to be correlated with markers of inflammation and to be predictive of coronary atherosclerosis and type II diabetes in humans. A common single nucleotide polymorphism (SNP) (−420C/G) in the promoter of resistin is associated with increased resistin plasma levels and susceptibility to type II diabetes. The aim of this study was to investigate the association of the -420C/G polymorphism with metabolic syndrome, obesity, myocardial infarction and kidney disease. Design and results.  First we studied 1542 subjects from the PLIC study (a population based cohort). GG carriers showed an higher prevalence of obesity and metabolic syndro…

AdultMalemedicine.medical_specialtyHeart diseaseGenotypeMyocardial InfarctionAdipokineGene ExpressionSingle-nucleotide polymorphismPolymorphism Single NucleotideCohort StudiesInternal medicineInternal MedicinemedicineHumansGenetic Predisposition to DiseaseResistinMyocardial infarctionObesityRNA MessengerPromoter Regions GeneticAgedMetabolic SyndromeFramingham Risk Scorebusiness.industryMiddle Agedmedicine.diseaseLipidsEndocrinologyKidney dysfunction metabolic syndrome myocardial infarction PBMC resistins SNPChronic DiseaseResistinFemaleKidney DiseasesMetabolic syndromebusinessKidney diseaseJournal of internal medicine
researchProduct

Plasma resistin levels are associated with homocysteine, endothelial activation, and nitrosative stress in obese youths.

2013

To evaluate whether serum resistin levels are related to cardiovascular risk in obese children.Cross-sectional study of 110 children (40 normal weight and 70 severely obese). Clinical and biochemical parameters, including lipid profile, fasting glucose and insulin, and homocysteine, were determined. The levels of adipokines (adiponectin, leptin, and resistin), markers of inflammation (high-sensitivity C-reactive protein (hs-CRP)), endothelial activation (serum concentrations of soluble intercellular and vascular cellular adhesion molecule-1 (sICAM-1, sVCAM-1)), and oxidative/nitrosative stress (malondialdehyde and urinary nitrate/nitrite) were measured.A partial correlation adjusted by gend…

AdultMalemedicine.medical_specialtyHomocysteineAdolescentNitrosationClinical BiochemistryAdipokineBody Mass IndexEndothelial activationchemistry.chemical_compoundYoung AdultInternal medicinemedicineHumansResistinObesityEndothelial dysfunctionHomocysteinemedicine.diagnostic_testAdiponectinbusiness.industryLeptinGeneral Medicinemedicine.diseaseEndocrinologychemistryResistinFemaleEndothelium VascularbusinessLipid profilehormones hormone substitutes and hormone antagonistsClinical biochemistry
researchProduct

Inflammation status of healthy young men: initial and specific responses to resistance training

2017

Our primary aim was to study the effects of a 4-week preparatory resistance-training (RT) period followed by 12 weeks of 2 specific RT protocols (either hypertrophic-strength (HS) or strength-hypertrophy-power training) on inflammation markers and the possible relationship of the changes in abdominal fat and lean mass to the changes in inflammation status. A total of 82 healthy men were included in the study. Maximal concentric leg press strength (1-repetition maximum), total body lean mass, total body and abdominal fat mass, circulating high-sensitivity C-reactive protein, interleukin-6, interleukin-1 receptor antagonist (IL-1ra), monocyte chemoattractant protein 1 (MCP-1), and selected a…

AdultMalemedicine.medical_specialtyPhysiologyEndocrinology Diabetes and MetabolismAdipokine030209 endocrinology & metabolismInflammation03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumansLeg pressInflammationNutrition and DieteticsAdiponectinbusiness.industryMuscle adaptationLeptinResistance Training030229 sport sciencesGeneral MedicineEndocrinologyLean body massResistinmedicine.symptombusinessBiomarkersApplied Physiology, Nutrition, and Metabolism
researchProduct

Elevated peripheral visfatin levels in narcoleptic patients.

2008

OBJECTIVE: Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin) producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients. METHODS: For the analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the Internatio…

AdultMalemedicine.medical_specialtyPolysomnographyNicotinamide phosphoribosyltransferaseAdipokineExcessive daytime sleepinesslcsh:MedicinePolysomnographyBody Mass IndexProinflammatory cytokineDiabetes and Endocrinology/Obesitychemistry.chemical_compoundReference ValuesInternal medicinemedicineHumansHLA-DR2 AntigenAge of OnsetNicotinamide Phosphoribosyltransferaselcsh:ScienceAgedNarcolepsySleep disorderMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RMiddle Agedmedicine.diseaseOrexinEndocrinologyMental Health/Sleep Disordersnervous systemchemistryImmunologyCytokinesFemalelcsh:Qmedicine.symptomImmunology/Genetics of the Immune SystembusinessResearch ArticleNarcolepsyPLoS ONE
researchProduct

Association of Serum Retinol Binding Protein 4 with Atherogenic Dyslipidemia in Morbid Obese Patients

2013

Retinol binding protein 4 (RBP4) is an adipokine that may contribute to the development of insulin resistance. However, how this adipokine is affected and its possible involvement in lipid metabolism in obese patients with varying degrees of insulin resistance is yet to be determined. A total of 299 middle-aged morbid obese patients (BMI>40 kg/m(2)) were divided in euglycemic, metabolic syndrome or type 2 diabetic. Anthropometric measurements, biochemical variables and systemic RBP4 levels were determined. RBP4 levels were significantly higher in patients with metabolic syndrome and type 2 diabetes than in euglycemic subjects (42.9±14.6; 42.3±17.0 and 37.4±11.7 µg/ml, respectively) and corr…

AdultMalemedicine.medical_specialtyVery low-density lipoproteinScienceCholesterol VLDLAdipokineType 2 diabetesBody Mass Indexchemistry.chemical_compoundInsulin resistanceInternal medicinemedicineHumansTriglyceridesDyslipidemiasMetabolic SyndromeRetinol binding protein 4MultidisciplinarybiologyCholesterolbusiness.industryCholesterol HDLQRCholesterol LDLMiddle AgedAtherosclerosisLipid Metabolismmedicine.diseaseObesity MorbidRetinol binding proteinEndocrinologyDiabetes Mellitus Type 2chemistryMultivariate Analysisbiology.proteinMedicineFemaleInsulin ResistanceMetabolic syndromebusinessRetinol-Binding Proteins PlasmaResearch ArticlePLoS ONE
researchProduct